New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...
FierceBiotech1d
Gura's weekly amylin obesity asset well tolerated, tied to weight loss in phase 1 trial
GUBamy is part of the investigational amylin field, a burgeoning landscape that includes Novo Nordisk’s CagriSema, a ...
Yahoo6d
New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently ...
ThePrint on MSN1d
Ozempic on steroids? Successor that could cut down weight in half the time coming soon
While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...
malaymail7d
Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy
LONDON, Nov 7 — Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar ...
Quartz on MSN8d
A new stronger Ozempic is coming. Here's what to know
Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Morningstar9d
Novo Nordisk Earnings: Maintaining Our Valuation as Key Cagrisema Data Approaches
We assign most of Novo’s obesity sales growth to the semaglutide molecule, but if cagrisema data is positive later this year, we are likely to raise our sales estimates for the drug in diabetes ...